About Chong Kun Dang Pharmaceutical
Chong Kun Dang Pharmaceutical is a pharmaceutical company engaged in the manufacturing and sales of prescription, OTC, health supplement and consumer health products. The company claims to have one of Koreas largest plants for chemical synthesis and fermentation, and also to be the first Korean company to export to the US. The company is focused on in-licensing novel drugs for chronic disorders such as diabetes and cardiovascular diseases, and also for anti-cancer therapies and neurological diseases. The companys current pipeline includes CKD-516 and CKD-581 (best-in-class drugs for cancer), CKD-519 (for dyslipidemia therapy), and also an in-house technology platform for developing HDAC6-selective inhibitors. The company also has marketing and sales partnerships with Bayer, Roche, Allergan, Pfizer, and MSD.
- Headquarter Seoul, South Korea
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Chong Kun Dang Pharmaceutical Corp.
-
Annual Revenue
$1.08 B (USD)-4.97as on Dec 31, 2024
-
Net Profit
$73.53 M (USD)-48.97as on Dec 31, 2024
-
EBITDA
$94.41 M (USD)-50.91as on Dec 31, 2024
-
Latest Funding Round
-
Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Chong Kun Dang Pharmaceutical
Chong Kun Dang Pharmaceutical is a publicly listed company on the KRX with ticker symbol 185750 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Unlock access to complete
Unlock access to complete
Funding Insights of Chong Kun Dang Pharmaceutical
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by Chong Kun Dang Pharmaceutical
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Chong Kun Dang Pharmaceutical
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Chong Kun Dang Pharmaceutical Comparisons
Competitors of Chong Kun Dang Pharmaceutical
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Chong Kun Dang Pharmaceutical
Frequently Asked Questions about Chong Kun Dang Pharmaceutical
When was Chong Kun Dang Pharmaceutical founded?
Chong Kun Dang Pharmaceutical was founded in 1941.
Where is Chong Kun Dang Pharmaceutical located?
Chong Kun Dang Pharmaceutical is headquartered in Seoul, South Korea.
Who is the current CEO of Chong Kun Dang Pharmaceutical?
Kim Young is the current CEO of Chong Kun Dang Pharmaceutical.
What is the annual revenue of Chong Kun Dang Pharmaceutical?
Annual revenue of Chong Kun Dang Pharmaceutical is $1.08B as on Dec 31, 2024.
What does Chong Kun Dang Pharmaceutical do?
Chong Kun Dang Pharmaceutical is a pharmaceutical company engaged in the manufacturing and sales of prescription, OTC, health supplement and consumer health products. The company claims to have one of Koreas largest plants for chemical synthesis and fermentation, and also to be the first Korean company to export to the US. The company is focused on in-licensing novel drugs for chronic disorders such as diabetes and cardiovascular diseases, and also for anti-cancer therapies and neurological diseases. The companys current pipeline includes CKD-516 and CKD-581 (best-in-class drugs for cancer), CKD-519 (for dyslipidemia therapy), and also an in-house technology platform for developing HDAC6-selective inhibitors. The company also has marketing and sales partnerships with Bayer, Roche, Allergan, Pfizer, and MSD.
Is Chong Kun Dang Pharmaceutical publicly traded?
Yes, Chong Kun Dang Pharmaceutical is publicly traded on KRX under the ticker symbol 185750.
What is Chong Kun Dang Pharmaceutical's ticker symbol?
The ticker symbol of Chong Kun Dang Pharmaceutical is 185750 on KRX.